Shots:
- Frontier has granted LG Chem an exclusive global license to develop & commercialize FMC-220 outside of Greater China, with Frontier retaining full rights in Greater China
- As per the deal, LG will handle regulatory filings, global clinical development, & commercialization in licensed regions, while Frontier may partially fund confirmatory trials & receive upfront, clinical, regulatory, & commercial milestone payments, & mid-single to double-digit royalties on net sales
- FMC-220, discovered using the Frontier platform, is a covalent p53 Y220C activator being evaluated for the treatment of solid tumor cancers with TP53 loss-of-function mutations
Ref: Businesswire | Image: LG Chem & Frontier Medicines | Press Release
Related News: Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
